Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226485 · ClinicalTrials.gov registry record · Phase 1
A Study in Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01226485 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 84 participants.
The verdict
NCT01226485, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Interventions
- DRUG Taladegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01226485
The ClinicalTrials.gov registry entry for NCT01226485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Taladegib is the first listed.
NCT01226485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01226485 about?
NCT01226485 is a clinical study titled "A Study in Advanced Cancer". The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study wi...
What is the current status of trial NCT01226485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2010-09. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01226485?
The interventions under investigation include: Taladegib (DRUG).
Who is sponsoring clinical trial NCT01226485?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.